BIBLIOGRAPHY
BIBLIOGRAPHY


49. Hanauer B, Sandborn J, Dallaire C. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol. 2007; 21:827-834.


69. Klebl H., Bataille F., Bertea R., Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with


118. Sands B, van Deventer S, Blank M. maintenance infliximab is safe and effective in fistulizing Crohn’s disease (CD); Results from the ACCENT II trial. Am J Gastroenterol. 2002; 97: S258.


121. Sartor B. Clinical applications of advances in the genetics of IBD. Rev Gastroenterol Disord. 2003; 3(suppl 1): S9-S17.


133. Takaishi H, Kanai T, Nakazawa A. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype J Gastroenterol. 2012; 47: 969.
